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OBSERVATIONS
Subclinical
Hypothyroidism Is
Associated With
Reduced All-Cause
Mortality in Patients
With Type 2
Diabetes
Subclinical hypothyroidism has beenassociated with a greater prevalenceof cardiovascular disease (1) and is
relatively common in patients with type 2
diabetes (2). If subclinical hypothyroid-
ism contributed to an increase in cardio-
vascular risk, then, intuitively, its effect
would be exaggerated in patients with
type 2 diabetes.
Patients were identified from a diabe-
tes database at Hull Royal Infirmary from
1993–2005 for retrospective analysis.
From the database, 6,540 consecutive pa-
tients enrolled through the end of 2000
were selected, and 472 patients with type
2 diabetes who had a raised thyrotropin-
stimulating hormone (TSH) (on two oc-
casions 6 months apart) and normal free
T4 (fT4) were identified (subsequent
case-note review reduced this number to
394 patients). They were compared with
472 consecutive age-matched type 2 dia-
betic patients with TSH 0.5–3.0 mU/l.
Sample size was powered to detect a dif-
ference between case subjects and control
subjects of 90% (1). TSH assays were per-
formed on AxSYM ultrasensitive hTSHII
Assay (normal 0.49–4.67 mIU/l), and
fT4 assays were performed on AxSYM
FT4 Assay (normal 9–24 pmol/l; Abbott
Diagnostics Division, U.K.). There was no
change in assay during the study period.
The relationship between subclinical
hypothyroidism and cardiovascular mor-
tality was assessed by logistic regression.
The case and control subjects were
matched by age (1:1 pair-wise matching).
Matching was broken and analyzed as in-
dependent sets by unconditional logistic
regression because this method is prefer-
able when the groups are very different to
except for the matching variable (3). Data
are presented as means  SEM.
Mean age of patients with subclinical
hypothyroidism was 73.1  0.6 versus
71.1 0.8 years in patients without sub-
clinical hypothyroidism. There were
more female subjects in patients with sub-
clinical hypothyroidism (83.7%) than in
the other group (18%). BMI, blood pres-
sure, lipid profile, A1C (8.2  0.1 vs.
8.1 0.1%), and background cardiovas-
cular disease were comparable. The mean
TSH level in patients with subclinical hy-
pothyroidism was 8.1  0.01 versus
1.1 0.02 mmol/l, whereas mean fT4 in
patients with subclinical hypothyroidism
was 12.2 0.2 versus 14.3 0.3 pmol/l
in patients without subclinical hypothy-
roidism. The mean duration from the di-
agnosis of subclinical hypothyroidism
was 7.9 years.
There were 222 new cardiovascular
events in patients with subclinical hypo-
thyroidism versus 246 events in patients
without subclinical hypothyroidism.
There were 96 (24.4%) all-cause mortali-
ties in patients with subclinical hypothy-
roidism versus 155 (32.8%) in patients
without subclinical hypothyroidism.
There were 47 (11.9%) noncardiovascu-
lar mortalities in patients with subclinical
hypothyroidism (respiratory, 30; neo-
plasm, 12; other, 5) versus 103 (21.8%)
in the other group (respiratory, 79; neo-
plasm, 18; other, 6).
There was no relationship between
baseline TSH and cardiovascular mortal-
ity. The unadjusted odds ratio (OR) for
cardiovascular mortality was 1.17 (95%
CI [0.89–1.53]; P  0.25). Adjusting for
age, sex, or the other covariates did not
alter the nature of this relationship. The
unadjustedOR for all-causemortality was
0.40 (0.30–0.56; P 0.01) and, after ad-
justing for covariates, 0.41 (0.12–0.98;
P  0.01).
Patients with subclinical hypothy-
roidism and type 2 diabetes did not have
an increased cardiovascular mortality
than patients with type 2 diabetes without
subclinical hypothyroidism. Unexpect-
edly, there was a significant reduction in
all-cause mortality in patients with sub-
clinical hypothyroidism and diabetes.
These data are in accord with studies
showing that elderly individuals with
higher levels of TSH were found to have a
prolonged life (4,5). In conclusion, sub-
clinical hypothyroidism may have a pro-
tective effect on noncardiovascular
mortality in type 2 diabetes; however, it is
not additive to relative higher cardiovas-
cular risk in type 2 diabetic patients 5
years after its diagnosis.
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